Background. Few longitudinal studies have described the interactions between reactivation of herpes simplex virus type 2 (HSV-2) infection (hereafter, "HSV-2 reactivation") and genital and systemic replication of human immunodeficiency virus type 1 (HIV-1).
ous epidemiological studies have shown that HSV-2 infection increases the risk of HIV type 1 (HIV-1) acquisition by ϳ3-fold [3] , but few studies have described the possible effects of HSV-2 infection on HIV-1 infectivity. Cross-sectional studies of women in Mombasa [4] and Bangui [5] have shown positive correlations between the quantities of genital HIV-1 RNA and genital HSV-2 DNA in persons coinfected with these viruses, whereas a Zimbabwean study did not find any association [6] . The high variability of HIV-1 and HSV-2 genital shedding, both within and between individuals, has been widely reported in large studies from the United States that involved daily sampling [7] [8] [9] , highlighting the need for a longitudinal design with multiple measurement points in order to best describe HIV-1 and HSV-2 genital shedding and identify their correlates.
A randomized placebo-controlled trial of therapy to suppress reactivation of HSV-2 infection (hereafter, "HSV suppressive therapy") was recently conducted in Burkina Faso on women who were coinfected with HIV-1 and HSV-2 and not eligible for highly active antiretroviral therapy (HAART) [10] . The trial showed that subjects who received valacyclovir (1.0 g/day for 3 months) had a lower frequency of HIV-1 RNA detection and a lower genital HIV-1 RNA load than subjects who received placebo, as well as a plasma HIV-1 RNA load that decreased by 0.5 log 10 copies/mL [10] . These findings suggest a possible effect of HSV-2 infection on the sexual transmissibility and the natural history of HIV-1 and highlight the potential of HSV suppressive therapy or other effective HSV control strategies as tools to prevent HIV infection [11, 12] . To choose appropriate strategies for relevant populations, it is important to determine the relative roles of clinical and subclinical reactivations of HSV-2 infection (hereafter, "HSV-2 reactivations") in the promotion of HIV-1 replication. In addition, the level of immunosuppression may be a major modulator of the effect of HSV-2 on HIV-1 replication. Decreased immunity has been responsible for more-frequent and more-severe HSV-2 reactivations [13, 14] and for higher rates of HIV-1 replication [15] . Therefore, the level of HIVinduced immunosuppression should be taken into account when describing and assessing the interactions between the 2 viruses.
The prerandomization phase of the ANRS1285a trial, which involved 6 visits on alternate weeks over 3 months, provided an opportunity to examine the roles of clinical and subclinical HSV-2 replication over time and the level of immunosuppression on HIV-1 replication.
PATIENTS, MATERIALS, AND METHODS
Enrollment criteria. The present analyses include women enrolled in the longitudinal baseline phase of the ANRS1285a trial conducted by Centre Muraz in Bobo-Dioulasso, Burkina Faso. Details of the design and methods of this trial have been reported elsewhere [10] . In brief, high-risk women who had serum antibodies to HIV-1 and to HSV-2 (detected by HSV-2 gG2 ELISA [Kalon]), had no contraindication to valacyclovir, and were not eligible for HSV suppressive therapy (because they had Ͼ6 clinical ulcer episodes annually) or antiretroviral therapy (because they had a CD4 ϩ cell count of Ͻ200 cells/L or any AIDSdefining condition [16] ) were enrolled in the trial. Laboratory analyses. At a screening visit for trial eligibility, venous blood samples were collected for serological detection of HIV-1, HSV-2, and Treponema pallidum; to assess renal and liver functions; and to determine the CD4 ϩ cell count, using standard fluorocytometry (FacScan [Becton Dickinson]). Urine specimens were obtained monthly for pregnancy testing. Eligible women who provided written informed consent were enrolled into the baseline phase of the trial, which consisted of 6 visits on alternate weeks over a 12-week period, before randomization to receive study drugs. At each visit, a study physician administered a standardized behavioral and clinical questionnaire, performed a physical examination, and collected the following genital specimens: vaginal swab specimens, obtained by conventional methods [10] , for the diagnosis of vaginal infections (Trichomonas vaginalis infection, Candida albicans infection, and bacterial vaginosis); and cervicovaginal lavage enriched by cervical swabbing, performed as previously described [17, 18] , to detect and quantify the levels of genital HIV-1 RNA and HSV-2 DNA. Genital and plasma HIV-1 RNA and genital HSV-2 DNA were detected and quantitated using a real-time polymerase chain reaction (PCR) technique, which was validated for HIV-1 strains circulating in West Africa [18] . For genital HIV-1 RNA, the detection threshold was 250 copies/mL [19] , and for plasma HIV-1 RNA, the detection threshold was 300 copies/mL [18] . For genital HSV-2 DNA, a detection threshold of 500 copies/mL was used [19] . At the first visit, cervical swab specimens were also obtained for the diagnosis of Neisseria gonorrhoeae infection and Chlamydia trachomatis infection by PCR (Amplicor NG/CT [Roche Diagnostics]). Genital specimens were not collected from menstruating women until 2 days after bleeding had ceased. The plasma HIV-1 RNA load was quantitated monthly with a real-time PCR technique, as described elsewhere [17, 18] . All participants were counseled at the start of the study about HSV-2 infection and clinical reactivations and were asked to return promptly to the clinic if they experienced an episode of genital ulcer disease (GUD) between follow-up visits. A gynecological examination was undertaken at each follow-up visit to determine the presence of GUD. Swabs of lesions were collected from clinically confirmed ulcers before any treatment was initiated and were tested for HSV-2 DNA by type-specific PCR [17] , using the same methods and thresholds as those described for cervicovaginal lavage. HIV counseling, drugs (when appropriate), and free condoms were provided at each visit. GUD treatment, which followed the national guidelines, involved syndromic first-line antibiotic treatment; women with ulcers that had not healed within 7 days received acyclovir (200 mg 5 times per day for 5 days). The study protocol was approved by the institutional review board at Centre Muraz and by the research ethics committees of the Burkina Faso Ministry of Health and the London School of Hygiene & Tropical Medicine.
Statistical analyses. All analyses were conducted using Stata statistical software, version 9.0 (StataCorp). In this study, we included data obtained during the longitudinal baseline phase from all eligible women who were subsequently randomized to receive study drugs and who were included in the trial analysis.
Detection of genital HIV-1 RNA during 1 visit, percentages of visits during which HIV-1 genital shedding was detected, and mean genital and plasma HIV-1 RNA loads were compared between the groups of women who experienced 1 GUD episode during follow-up and women who did not experience GUD, as well as between the groups of women in whom HSV-2 genital shedding was detected at least once during follow-up and women in whom HSV-2 genital shedding was not detected. To assess the role of immunosuppression, results were stratified by CD4 ϩ cell count at study entry (200 -500 cells/L and Ͼ500 cells/L).
Detection of genital HIV-1 RNA and the percentage of visits during which HIV-1 genital shedding was detected underwent summary-measures analyses that combined the data for each woman into a single value. The association between the detection of genital HIV-1 RNA at any time during follow-up and the occurrence of a GUD episode or HSV-2 genital shedding during follow-up was estimated as a risk ratio (RR), using Poisson regression with robust SEs [20] . The percentage of visits during which genital HIV-1 RNA was detected, based on detection of GUD or HSV-2 genital shedding at 1 visit, was estimated by an ordered logistic regression model and expressed as an odds ratio (OR) with a 95% confidence interval (CI). A per-visit analysis was used to evaluate the association between the detection of genital HIV-1 RNA and the presence of GUD or HSV-2 DNA, using a Poisson regression with robust SEs.
Virus loads were log 10 transformed to obtain approximately normal distributions. Values under the threshold of detection for each assay were given half the value of that threshold and were log 10 transformed. The association between the mean genital HIV-1 RNA load and the detection of GUD or HSV-2 genital shedding was assessed per visit by use of linear regression models, allowing for within-woman correlations among visits during which genital HIV-1 RNA was detected, because of the relatively high proportion of nonshedders at each visit. The associations between the plasma HIV-1 RNA load and the detection of GUD or HSV-2 genital shedding were assessed similarly among all visits during which HIV-1 RNA was detected. Linear regression models allowing for within-woman correlation were also used to assess the association between the mean genital HIV-1 RNA load and detection of genital HSV-2 DNA at visits during which genital HIV-1 RNA was detected. Secondary analyses included testing effect modification by CD4 ϩ cell count categories. Within-woman correlation is presented as the intracluster correlation (ICC) calculated from random-effects models in Stata. The 95% CI for the ICC was estimated using the formula described by Donner and Koval [21] .
RESULTS
Details of the study population and follow-up visits have been published previously [10] . Briefly, the 140 women who completed the baseline phase and were subsequently randomized in the ANRS1285a trial [10] were eligible for this study. Four women were excluded because they were enrolled by mistake, leaving 136 women in this analysis. Of 816 potential visits during the follow-up period, 784 (96%) were completed. Missed visits mainly occurred on menstruation days.
Relationship between plasma HIV-1 RNA load and CD4 ؉ cell count. Participants were moderately immunosuppressed, with a median CD4 ϩ cell count of 446 cells/L (interquartile range, 334 -628 cells/L). The CD4 ϩ cell count was Ͼ500 cells/L in 56 women (41.8%) and 200 -500 cells/L in 78 (58.2%) at study entry; data were not available for 2 women. Only 5 women (3.7%) had a plasma HIV-1 RNA load that was below the detection threshold of 300 copies/mL at all visits (table  1) , and none of these women had genital HIV-1 RNA detected during the follow-up period. In contrast, 115 (87.9%) of 131 women with HIV-1 RNA detected in plasma at least once had genital HIV-1 RNA detected at least once. There was a high degree of within-woman correlation of plasma HIV-1 RNA load (ICC, 0.70; 95% CI, 0.63-0.77).
Relationship between detection of genital HSV-2 DNA and GUD status. Genital HSV-2 DNA was detected in 61 (44.9%) of 136 women at least once but during only 88 (11.2%) of 784 visits (table 1) . There was significant within-patient correlation of having HSV-2 genital shedding detected during follow-up (ICC, 0.21; 95% CI, 0.10 -0.38). There was no clear relationship between detection of GUD and detection of genital HSV-2 DNA during follow-up: 21 (53.8%) of 39 women with GUD detected during 1 visit had HSV-2 genital shedding detected at least once, compared with 41.2% of those in whom GUD was not detected during follow-up (P ϭ .18). However, genital HSV-2 DNA was more frequently detected during visits in which GUD was detected, compared with visits during which GUD was not detected (37.5% vs 9.8%; P Ͻ .001). GUD was present on 15 (17.1%) of 88 visits during which HSV-2 genital shedding was detected. Of 27 visits during which GUD was detected and a lesion swab was available, genital HSV-2 DNA was detected by PCR in 14 (51.9%).
Relationships between detection of genital HIV-1 RNA and GUD status, CD4 ؉ cell count, and detection of genital HSV-2 DNA. Overall, 115 women (84.6%) had genital HIV-1 RNA detected at least once during follow-up, of whom 75.6% had genital HIV-1 RNA detected during 50% of visits. There was significant within-patient correlation of having HIV-1 genital shedding detected (ICC, 0.49; 95% CI, 0.38 -0.60) and of the magnitude of the genital HIV-1 RNA load during visits when HIV-1 shedding was detected (ICC, 0.30; 95% CI, 0.17-0.43). Women with GUD detected at least once had a higher risk of having genital HIV-1 RNA detected at least once (RR, 1.23; 95% CI, 1.09 -1.37; P Ͻ .001). Similarly, women with genital HSV-2 DNA detected at least once were more likely to have genital HIV-1 RNA detected at least once, compared with women without genital HSV-2 DNA detected during 1 visit (91.8% vs. 78.7%; RR, 1.17; 95% CI, 1.01-1.34) (table 2).
Detection of genital HIV-1 RNA at least once during follow-up was more common among women with a CD4 ϩ cell count of 200 -500 cells/L (93.6%) than among women with a CD4 ϩ cell count of Ͼ500 cells/L (73.2%; P ϭ .001). The association between detection of GUD at least once and detection of genital HIV-1 RNA at least once was stronger among women with a higher CD4 ϩ cell count (table 2) . A similar trend was observed between detection of genital HSV-2 DNA during 1 visit and detection of genital HIV-1 RNA during 1 visit among women with a higher CD4 ϩ cell count. Detection of GUD at 1 follow-up visit was also associated with a greater percentage of visits during which HIV-1 genital shedding was detected (OR, 2.79; 95% CI, 1.4 -5.7; P ϭ .005). Again, this risk was stronger among women with a higher CD4 ϩ cell count (table 2) . Women in whom genital HSV-2 DNA was detected at least once also tended to have HIV-1 shedding detected during a greater percentage of visits (OR, 1.71; 95% CI, 0.9 -3.2; P ϭ .10).
Effects of GUD and HSV-2 reactivation on plasma HIV-1 RNA load. The mean plasma HIV-1 RNA level among women with GUD detected at 1 visit was 0.25 log 10 copies/mL (95% CI, Ϫ0.05-0.55) greater than that among women in whom GUD was not detected (P ϭ .11) (table 3), with a trend toward a stronger effect with a lower CD4 ϩ cell count. Similarly, the mean plasma HIV-1 RNA level among women who had HSV-2 genital shedding detected at least once was 0.40 log 10 copies/mL (95% CI, 0.15-0.66) greater than that among women in whom HSV-2 genital shedding was not detected during follow-up (P ϭ .002).
Finally, we compared the detection of genital HIV-1 RNA and the magnitude of the genital HIV-1 RNA load between the following 3 groups: visits during which GUD was detected, with or without concomitant detection of genital HSV-2 DNA; visits during which genital HSV-2 DNA was detected but GUD was not detected; and visits during which neither GUD nor genital HSV-2 DNA were detected (table 4). The genital HIV-1 RNA load was significantly higher at visits during which genital HSV-2 DNA but not GUD was detected (3.79 log 10 copies/mL; 95% CI, 3.53-4.04) and visits during which GUD was detected (4.02 log 10 copies/mL; 95% CI, 3.77-4.27), compared with visits during which GUD and HSV-2 genital shedding were not detected (3.56 log 10 copies/mL; 95% CI, 3.49 -3.64). A comparison of visits during which neither GUD nor HSV-2 genital shedding were detected with visits during which genital HSV-2 DNA but not GUD was detected revealed some evidence of an effect modification of CD4 ϩ cell count (P for interaction ϭ .08), but such evidence was not apparent in a comparison between visits during which GUD was detected and visits during which neither GUD nor HSV-2 genital shedding were detected (P for interaction ϭ .33). Mean plasma HIV-1 RNA loads were significantly higher at visits during which GUD was detected (P ϭ .04) and visits during which genital HSV-2 DNA but not GUD was detected (P ϭ .001), compared with visits during which neither HSV-2) and human immunodeficiency virus type 1 RNA (HIV-1)  loads and frequency of HSV-2 and HIV-1 detection, a Data are proportion (%) of women or mean log 10 copies/mL (95% confidence interval).
b Data are proportion (%) of visits or mean log 10 copies/mL (95% confidence interval).
c Data are for visits during which the plasma HIV-1 load was detectable.
GUD nor genital HSV-2 DNA were detected; in both comparisons, the mean plasma HIV-1 RNA loads were ϳ0.5 log 10 copies/mL greater than that detected at visits during which neither GUD nor genital HSV-2 DNA were detected. Again, there was no suggestion that these associations were influenced by the CD4 ϩ cell count (P for interaction ϭ .54 for the comparison involving visits during which genital HSV-2 DNA but GUD was detected, and P for interaction ϭ .71 for the comparison involving visits during which GUD was detected).
DISCUSSION
Our findings suggest that, among women coinfected with HIV-1 and HSV-2 who were moderately immunosuppressed and not taking antiretroviral therapy, clinical or subclinical HSV-2 reactivations were associated with a detection of HIV-1 genital shedding during a greater percentage of clinic visits and with greater genital and plasma HIV-1 RNA loads (ϩ0.5 log 10 copies/mL). These associations were seen at both lower (200 -500 cells/L) and higher (Ͼ500 cells/L) CD4 ϩ cell counts. The role of HSV-2 reactivation was probably more modest in the subgroup of women with a CD4 ϩ cell count of Ͻ500 cells/L, as almost all of these women had detectable genital HIV-1 RNA. Few longitudinal studies have reported the relationships between the frequency of HIV-1 RNA detection and levels of genital and plasma HIV-1 RNA detected with the presence of clinical and subclinical HSV-2 reactivations. Studies among American homosexual men have shown increased levels of HIV-1 RNA in lesion specimens during HSV-2 ulcerations [22] and temporarily increased levels of plasma HIV-1 RNA after clinical or subclinical HSV-2 reactivations [22, 23] . By contrast, a study of 38 American women failed to show any effect of HSV-2 shedding on plasma HIV-1 RNA loads [24] , possibly because three-quarters of participants were taking antiretrovirals. In Rakai, Uganda, persons who seroconverted to HIV-1 and were previously infected with HSV-2 had higher plasma HIV-1 RNA set points [25] , but differences in relation to HSV-2 reactivations among HSV-2-infected individuals were not reported.
Our findings suggest that both clinical and subclinical HSV-2 reactivations are important in influencing HIV-1 replication. Relationships between detection of genital ulcer disease and genital herpes simplex virus type 2 DNA (HSV-2) during 1  visit and genital human immunodeficiency virus type 1 (HIV-1) load, overall and ) for detection of genital HIV-1 during 1 visit. Odds ratios (ORs) were obtained by ordered logistic regression and are specified (with 95% CIs) for percentages of visits during which genital HIV-1 was detected.
b P for interaction with CD4 ϩ cell count as a continuous variable
This conforms with previous observations that herpetic clinical reactivations are linked to transient increases in plasma virus loads [23, 26, 27] . However, the relative roles of clinical and subclinical HSV-2 reactivations as distinct activators of HIV-1 replication are difficult to appraise because HSV-2 ulcerations are always preceded by HSV-2 genital shedding (i.e., by a subclinical reactivation). We assumed that the majority of GUD episodes in our setting were caused by HSV-2: 52% of lesion swabs yielded HSV-2, whereas the prevalence of other GUD pathogens has been found to be Ͻ2% in this population [28] . Our study has several strengths that were not present in previous studies. The observation of a difference between the frequency of HSV-2 shedding among women, using summary measures and the per-visit analysis, emphasizes the high withinperson variability of HSV-2 shedding and the need for a longitudinal design with multiple measurement points in order to obtain a more precise estimate of the associations between the 2 viruses. In addition, this design allowed reporting of both clinical and subclinical HSV-2 shedding episodes in the same woman over time. There were, however, some limitations in estimating these associations. In this placebo-controlled trial, we did not enroll women who had been experiencing frequent clinical (and probably subclinical) HSV-2 reactivations, because they were provided with HSV suppressive therapy to reduce the incidence of reactivations. Therefore, compared with an unselected population of coinfected women who did not require HAART, the strength of the associations between the 2 viruses and the effect of frequent GUD were probably underestimated in our study population. The occurrence of GUD is difficult to assess thoroughly during such short period (3 months in this study), and many episodes may have been missed because they occurred between follow-up visits or because of their anatomical localization and absence of accompanying symptoms. In addition, study physicians may have missed, despite careful examination, some very small ulcers and some intravaginal or cervical ulcers that could be confused with other lesions (e.g., cervical dysplasia or ectropion). Moreover, we may have missed HSV-2 shedding episodes occurring between visits, because of the intermittent nature of HSV-2 genital shedding. Such misclassifications may have introduced biases in our findings, which most likely underestimated the effect of HSV-2 reactivation on HIV-1 replication. Finally, we had low power to estimate the interactions by CD4 ϩ cell count, because this study was not initially designed for this purpose.
We suggest that the distinction between GUD and HSV-2 genital shedding may be instrumental in choosing appropriate HSV control strategies and in identifying relevant target groups for HIV prevention. For example, HSV-episodic therapy could be a feasible strategy in many settings in which HIV-infected patients are receiving treatment. However, targeting GUD episodes only would miss many individuals with subclinical reactivations, which contribute in similar ways to HIV-1 replication and which occurred much more frequently [29] . In addition, episodic treatment relies on recognition of clinical symptoms and on health care-seeking behavior, which may limit the population-level impact of this intervention. By contrast, HSV suppressive therapy bypasses the need to recognize symptoms. Its efficacy to prevent both clinical and subclinical HSV-2 reactivations [30] might result in a much larger public health impact [31] . In addition, HSV suppressive therapy may provide additional benefit by altering progression of HIV disease. The ANRS 1285a trial showed that women receiving valacyclovir had lower Table 3 . Relationships between detection of genital ulcer disease and genital herpes simplex virus type 2 DNA (HSV-2) during  1 visit and plasma human immunodeficiency virus type 1 RNA (HIV-1) plasma virus loads than women taking placebo [10] . This decrease might be accompanied by a slower decrease of the CD4 ϩ cell count with a longer duration of treatment [12] , but this effect should be verified through appropriate clinical trials.
In the absence of efficacious therapeutic HSV-2 vaccines, HSV suppressive therapy is the intervention of choice for HSV control. However, the optimal strategy of HSV control to prevent HIV acquisition is not clear. More than 70% of HIV-infected individuals may be coinfected with HSV-2 [1, 2] , but facilities to perform serological tests for HSV-2 are not widely available in many resource-constrained settings. Therefore, initiation of HSV suppressive therapy may be the most practical option for HIV-infected individuals in such settings. As a first step, HIVinfected individuals with a known serostatus who present with GUD could be offered HSV suppressive therapy first. In this case, HSV-2 counseling and education interventions should be adapted and made available as part of HIV management strategies, to increase recognition of HSV symptoms among HIVinfected individuals [7, 32] . Health practitioners should be trained to raise their awareness about HSV-2, including the possibility to treat it. For settings where HSV-2 may be less prevalent or where more resources are available, efforts should perhaps be made to increase access to HSV-2 serological testing or to develop simple, reliable, and inexpensive point-of-care diagnostic tests.
Important remaining operational questions include the optimal time to start and stop HSV treatment for HIV prevention. Our findings suggest that the role of HSV-2 reactivations in HIV-1 replication may be more pronounced at higher CD4 ϩ cell counts, but this role should be further investigated in specifically designed studies. If these results are confirmed, it would be logical to initiate HSV suppressive therapy as soon as HIV-1 infection is diagnosed, because the relative influence of HSV-2 infection on HIV-1 replication would appear to be greater and antiretroviral therapy would unlikely be beneficial to such patients. This would potentially provide both a means to prevent onward transmission to uninfected sexual partners and to slow the progression of HIV disease, thus delaying the eligibility for Genital and plasma human immunodeficiency virus type 1 RNA (HIV-1) detection and load, overall and by CD4 ؉ cell count, among women who had genital ulcer disease (GUD) and/or genital herpes simplex virus type 2 DNA (HSV-2) detected during 1 visit. antiretroviral therapy. The duration of HSV suppressive therapy, however, remains speculative. We hypothesize that increased systemic HIV-1 replication due to HSV-2 will accelerate the decrease in the CD4 ϩ cell count that is, in turn, fueled over time by regular HSV-2 reactivations. If this is the case, HSV interventions should at best be continued until antiretroviral therapy becomes necessary. Prospective studies with a longer duration are required to confirm this hypothesis. The relevance of HSV suppressive therapy during antiretroviral therapy also deserves further investigation. We have reported a potential benefit of this strategy for women taking HAART in Burkina Faso [33] . In that study, women who still experienced HIV-1 genital shedding despite undetectable plasma virus loads (approximately half of all women) experienced significant reductions in the frequency of detection and the quantity of genital HIV-1 RNA during valacyclovir therapy, compared with women taking placebo. Such effects may help limit the emergence of HIV-1 resistance and may provide some benefit to patients in terms of HSV reactivations.
In conclusion, clinical and subclinical HSV-2 reactivations contribute to genital and systemic HIV-1 replication. HSV suppressive therapy is probably the best current strategy for HIV control, with the greatest benefit at the early stages of HIV-1 infection. The importance of HSV control for HIV prevention is increasingly becoming appreciated. The results of ongoing trials of HSV suppressive therapy for the prevention of HIV acquisition or transmission will be crucial in determining the role of this novel approach as an effective tool for HIV prevention.
